BIOLASE (NASDAQ:BIOL) Receives New Coverage from Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the medical technology company’s stock.

BIOLASE Price Performance

Shares of NASDAQ:BIOL opened at $0.15 on Friday. The company has a market cap of $4.92 million, a P/E ratio of 0.00 and a beta of 0.67. The company has a quick ratio of 0.68, a current ratio of 1.26 and a debt-to-equity ratio of 34.06. BIOLASE has a 52 week low of $0.13 and a 52 week high of $32.09. The business has a fifty day simple moving average of $0.15 and a 200-day simple moving average of $0.81.

BIOLASE (NASDAQ:BIOL) last announced its quarterly earnings data on Thursday, March 21st. The medical technology company reported ($1.76) EPS for the quarter. The business had revenue of $13.49 million during the quarter. BIOLASE had a negative net margin of 41.97% and a negative return on equity of 555.22%.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.